Iterum Therapeutics
Market Cap
US$97.5m
Last Updated
2019/08/18 01:14 UTC
Data Sources
Company Financials +
Executive Summary
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States.
Snowflake
Fundamentals
High growth potential and slightly overvalued.
Share Price & News
How has Iterum Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-0.6%
NasdaqGM:ITRM
-1.8%
US Pharmaceuticals
-1.0%
US Market
1 Year Return
-22.3%
NasdaqGM:ITRM
-6.6%
US Pharmaceuticals
-0.4%
US Market
ITRM underperformed the Pharmaceuticals industry which returned -6.6% over the past year.
ITRM underperformed the Market in United States of America which returned -0.4% over the past year.
Share holder returns
| ITRM | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.6% | -1.8% | -1.0% |
| 30 Day | 1.2% | -3.5% | -3.3% |
| 90 Day | -3.8% | -3.8% | 0.8% |
| 1 Year | -22.3%-22.3% | -4.3%-6.6% | 1.9%-0.4% |
| 3 Year | n/a | 7.9%0.6% | 39.4%30.4% |
| 5 Year | n/a | 22.9%10.0% | 54.2%37.1% |
Price Volatility Vs. Market
How volatile is Iterum Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Have Insiders Been Buying Iterum Therapeutics plc (NASDAQ:ITRM) Shares?1 month ago | Simply Wall St
How Many Iterum Therapeutics plc (NASDAQ:ITRM) Shares Do Institutions Own?2 months ago | Simply Wall St
Did Changing Sentiment Drive Iterum Therapeutics's (NASDAQ:ITRM) Share Price Down A Worrying 51%?Valuation
Is Iterum Therapeutics undervalued based on future cash flows and its price relative to the stock market?
>50%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Iterum Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
Iterum Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
Price Based on Earnings
Iterum Therapeutics is loss making, we can't compare its value to the US Pharmaceuticals industry average.
Iterum Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Iterum Therapeutics, we can't assess if its growth is good value.
Price Based on Value of Assets
Iterum Therapeutics is overvalued based on assets compared to the US Pharmaceuticals industry average.
Next Steps
Future Growth
How is Iterum Therapeutics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?
37.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Iterum Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Iterum Therapeutics's earnings are expected to grow significantly at over 20% yearly.
Iterum Therapeutics's revenue growth is expected to exceed the United States of America market average.
Iterum Therapeutics's earnings growth is expected to exceed the United States of America market average.
Iterum Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Iterum Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Next Steps
Past Performance
How has Iterum Therapeutics performed over the past 5 years?
-115.5%
Last years earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Iterum Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
Unable to compare Iterum Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Iterum Therapeutics's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Iterum Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Iterum Therapeutics has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Iterum Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Iterum Therapeutics's financial position?
Financial Position Analysis
Iterum Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Iterum Therapeutics's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Iterum Therapeutics's level of debt (58.1%) compared to net worth is high (greater than 40%).
Unable to establish if Iterum Therapeutics's debt level has increased without past 5-year debt data.
Balance Sheet
Low level of unsold assets.
Debt is covered by short term assets, assets are 4.2x debt.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Iterum Therapeutics has less than a year of cash runway based on current free cash flow.
Iterum Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 61.1% each year.
Next Steps
Dividend
What is Iterum Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Iterum Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Iterum Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Iterum Therapeutics has not reported any payouts.
Unable to verify if Iterum Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Iterum Therapeutics has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of Iterum Therapeutics's salary, the management and board of directors tenure and is there insider trading?
3.8yrs
Average management tenure
CEO
Corey Fishman (54yo)
3.8yrs
Tenure
US$1,757,007
Compensation
Mr. Corey N. Fishman has been the Chief Executive Officer of Iterum Therapeutics Ltd since November 2015 and serves as its President. Mr. Fishman served as the Chief Operating Officer and Chief Financial O ...
CEO Compensation Analysis
Corey's remuneration is higher than average for companies of similar size in United States of America.
Corey's compensation has increased whilst company is loss making.
Management Age and Tenure
3.8yrs
Average Tenure
54yo
Average Age
The tenure for the Iterum Therapeutics management team is about average.
Board Age and Tenure
3.0yrs
Average Tenure
54yo
Average Age
The tenure for the Iterum Therapeutics board of directors is about average.
Insider Trading
No 3 month open market individual insider trading information.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors |
| Shares | 10,000 |
| Max Price | US$6.29 |
| Entity | Company |
| Shares | 58,000 |
| Max Price | US$6.10 |
| Entity | Individual |
| Role | Chief Scientific Officer |
| Shares | 500 |
| Max Price | US$10.00 |
| Entity | Individual |
| Role | Chief Scientific Officer |
| Shares | 1,000 |
| Max Price | US$10.00 |
| Entity | Individual |
| Shares | 500 |
| Max Price | US$10.44 |
Ownership Breakdown
Management Team
Corey Fishman (54yo)
President
- Tenure: 3.8yrs
- Compensation: $1.76m
Mike Dunne (59yo)
Chief Scientific Officer
- Tenure: 3.8yrs
- Compensation: $1.15m
Judy Matthews (49yo)
Chief Financial Officer
- Tenure: 3.8yrs
- Compensation: $611.66k
Ben Pe
Vice President of Operations
- Tenure: 4.6yrs
Louise Barrett
Secretary
Board Members
Brent K. Ahrens (56yo)
Interim Chairman
- Tenure: 0.2yrs
- Compensation: $105.77k
Patrick Heron (49yo)
Director
- Tenure: 3.8yrs
- Compensation: $103.65k
Ron Hunt (54yo)
Director
- Tenure: 3.8yrs
- Compensation: $110.93k
Mohammed Shahzad Malik (52yo)
Director
- Tenure: 2.3yrs
- Compensation: $107.29k
Jim Healy (54yo)
Director
- Tenure: 3.8yrs
- Compensation: $104.86k
David Kelly (58yo)
Director
- Tenure: 3.0yrs
- Compensation: $120.53k
Corey Fishman (54yo)
President
- Compensation: $1.76m
Mark Chin (37yo)
Director
- Tenure: 2.3yrs
- Compensation: $109.41k
Company Information
Iterum Therapeutics plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Iterum Therapeutics plc
- Ticker: ITRM
- Exchange: NasdaqGM
- Founded: 2015
- Industry: pharmaceuticals
- Sector: pharmaceuticals & biotech
- Market Cap: US$97.509m
- Shares outstanding: 14.42m
- Website: Click here
Number of Employees
Location
- Iterum Therapeutics plc
- Harcourt Centre
- Block 2, Floor 3
- Dublin
- Co. Dublin
- 2
- Ireland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ITRM | NasdaqGM (Nasdaq Global Market) | Yes | Ordinary Shares | US | USD | May 2018 |
Biography
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulope ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/08/18 01:14 |
| End of Day Share Price | 2019/08/16 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.